KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017)

Arbutus Biopharma's Non-Current Debt history spans 2 years, with the latest figure at $12.0 million for Q4 2017.

  • For Q4 2017, Non-Current Debt changed 0.0% year-over-year to $12.0 million; the TTM value through Dec 2017 reached $12.0 million, changed 0.0%, while the annual FY2017 figure was $12.0 million, 0.0% changed from the prior year.
  • Non-Current Debt for Q4 2017 was $12.0 million at Arbutus Biopharma, roughly flat from $12.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $12.0 million in Q4 2016 and bottomed at $12.0 million in Q4 2016.